激动剂和抑制剂
在生物化学和药物化学领域中,激动剂和抑制剂是调节受体活性的重要分子类型。
激动剂:激动剂是指能够与特定受体结合并激活该受体,从而引起细胞内信号传递的化合物。它们通过与受体的特定位点相互作用,模拟天然配体的功能,导致生物效应的发生或增强。根据其对受体的作用机制不同,激动剂可以分为完全激动剂和部分激动剂。
完全激动剂:能够完全激活受体,达到最大生物活性。
部分激动剂:仅能部分地激活受体,即使在高浓度下也不表现出最大效应。
抑制剂:抑制剂则是相反的一类分子,它们通过与受体或其相关蛋白质结合来阻止信号传导过程。根据作用机制的不同,可以分为竞争性抑制剂和非竞争性抑制剂。
竞争性抑制剂:这些物质通过占据活性位点而减少激动剂的结合能力,通常可以通过增加激动剂浓度来克服这种抑制效应。
非竞争性抑制剂:这类抑制剂不依赖于受体结合部位,而是通过其他方式干扰信号传递,如改变受体构象或直接与G蛋白相互作用。
在药物研发过程中,激动剂和抑制剂的研究至关重要。它们不仅用于治疗疾病,还可以帮助理解生物系统的工作原理。例如,在神经科学领域,激动剂可以被用作治疗抑郁、焦虑等精神疾病的药物;而在癌症研究中,则可能使用抑制剂来阻断促进肿瘤生长的信号通路。
中文名称 | 英文名称 | CAS号 | 化学式 | 结构式图片 |
---|---|---|---|---|
—— | Pyr6 | 245747-08-4 | C17H9F7N4O |
|
—— | thiamet-G | 1009816-48-1 | C9H16N2O4S |
|
—— | (8R*,9S*,11S*)-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H, 8H, 11H-2, 7b, 11a-triazadibenzo(a,g)cycloocta(cde)trinden-1-one | 97161-97-2 | C27H21N3O5 |
|
—— | T16Ainh-A01 | 552309-42-9 | C19H20N4O3S2 |
|
—— | RTA 405 | 932730-51-3 | C33H46N2O3 |
|
—— | 1-(2-methylbenzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea | 249889-64-3 | C17H13N5O2 |
|
—— | 1-Piperazineacetamide, 4-((3-(7-chloro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indol-3-yl)-1,2,4-oxadiazol-5-yl)methyl)- | 1050478-18-6 | C23H29ClN6O3 |
|
—— | JNJ 39758979 | 1046447-90-8 | C11H19N5 |
|
—— | Posaconazole hydrate | 1198769-38-8 | C37H44F2N8O5 |
|
—— | N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide | 1604810-84-5 | C31H28ClN7O2 |
|
—— | TG-100801 Hydrochloride | 1018069-81-2 | C33H31Cl2N5O3 |
|
—— | (2R)-2-hydroxy-3-[(2S,6R,8S)-11-hydroxy-2-[(E,2R)-4-[(2S,2'S,4R,6R)-4-hydroxy-2-[(3S)-1-hydroxy-3-[(3R,6S)-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4H-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-4-methyl-1,7-dioxaspiro[5.5]undec-4-en-8-yl]-2-methylpropanoic acid | 78111-17-8 | C44H68O13 |
|
—— | Pirmavar | 61477-94-9 | C22H31ClN2O |
|
—— | Sodium;6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylic acid | 96201-88-6 | C23H15F2NNaO2+ |
|
—— | imino-methyl-[1-[6-(3-methylmorpholin-4-yl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-lambda6-sulfane | 1352226-88-0 | C20H24N6O2S |
|
—— | HA 130 | 1229652-21-4 | C24H19BFNO5S |
|
—— | 5-{3-[4-(Aminomethyl)phenoxy]propyl}-2-{(8E)-8-[2-(1,3-benzothiazol-2-yl)hydrazinylidene]-5,6,7,8-tetrahydronaphthalen-2-yl}-1,3-thiazole-4-carboxylic acid | 1431866-33-9 | C31H29N5O3S2 |
|
—— | Cyclohexanol, 4-(4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl)-, trans- | 193551-21-2 | C20H21FN4O2 |
|
—— | N-(3-methoxyphenyl)-4-chlorocinnamanilide | 1649486-65-6 | C16H14ClNO2 |
|
—— | Tauroursodeoxycholic acid sodium salt | 6009-98-9 | C26H44NO6S*Na |
|
—— | CX691 | 211735-76-1 | C12H13N3O2 |
|
—— | PIM447 | 1210608-43-7 | C24H23F3N4O |
|
—— | 1-(3-(4-cyanophenoxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea | 1400989-25-4 | C21H13ClF3N3O2 |
|
—— | 3-chloro-N-[4-(methylamino)cyclohexyl]-N-[(3-pyridin-4-ylphenyl)methyl]-1-benzothiophene-2-carboxamide | 912545-86-9 | C28H28ClN3OS |
|
—— | SAR405 | 1523406-39-4 | C19H21ClF3N5O2 |
|
—— | Nutlin-3 | 548472-68-0 | C30H30Cl2N4O4 |
|
—— | 5-chloro-4-(1H-indol-3-yl)-N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidin-2-amine | 1356962-34-9 | C29H34ClN7O |
|
—— | [N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulphonyl}-2-(2-methoxyphenyl)acetamide] | 915191-42-3 | C32H33N3O7S |
|
—— | vaniprevir | 923590-37-8 | C38H55N5O9S |
|
—— | H-89 | 127243-85-0 | C20H20BrN3O2S |
|
—— | spiculisporic acid | 469-77-2 | C17H28O6 |
|
—— | (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol | 167354-41-8 | C32H31F2N3O2 |
|
—— | 6-((1R,2S)-2-amino-cyclohexylamino)-4-(5,6-dimethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide | 1446790-62-0 | C18H25N7O |
|
—— | Y-27632 dihydrochloride | 146986-50-7 | C14H21N3O |
|
—— | bleomycin | 11056-06-7 | C55H84N17O21S3 |
|
—— | 3-methyl-2-((1S,2S)-2-(quinolin-2-yl)cyclopropyl)-3H-imidazo[4,5-f]quinoline | 1516896-09-5 | C21H19N7 |
|
—— | 5-(4-methoxy-<i>trans</i>-cinnamylidene)-barbituric acid | 100872-83-1 | C14H12N2O4 |
|
—— | (E)-3-(2,4-dimethoxybenzylidene)-3,4,5,6-tetra-hydro-2,3'-bipyridine dihydrochloride | 156223-05-1 | C19H20N2O2*2ClH |
|
—— | 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-2-(2-(6-((diethylamino)methyl)-2-pyridinyl)ethenyl)-6-fluoro- | 199655-36-2 | C26H24ClFN4O |
|
—— | (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide | 1223498-69-8 | C18H21F3N4O3S |
|
—— | DDD00175799 | 100872-83-1 | C14H12N2O4 |
|
—— | N-1R-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxyphenyl)-acetamide | 473719-41-4 | C32H28F3N5O4 |
|
—— | gold(1+);3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-thiolate | 12192-57-3 | C6H11AuO5S |
|
—— | N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine | 1239358-86-1 | C21H20FN7 |
|
—— | zosuquidar | 167465-36-3 | C32H31F2N3O2 |
|
—— | 2-[Bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid;gadolinium | 131410-48-5 | C16H29GdN5O8 |
|
—— | K-Ras G12C-IN-3 | 1629268-19-4 | C21H19Cl3N2O3 |
|
—— | sequella | 502487-67-4 | C22H38N2 |
|
—— | cenicriviroc | 497223-25-3 | C41H52N4O4S |
|
—— | potassium O-((3aR,4R,5S,7R,7aR)-octahydro-1H-4,7-methanoinden-5-yl) carbonodithioate | 473281-59-3 | C11H15OS2*K |
|